Chimerix Competitors

Deciphera Pharmaceuticals (NASDAQ:DCPH) and Chimerix (NASDAQ:CMRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Deciphera Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.

Institutional and Insider Ownership

73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 7.0% of Deciphera Pharmaceuticals shares are owned by insiders. Comparatively, 9.0% of Chimerix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Deciphera Pharmaceuticals and Chimerix's top-line revenue, earnings per share and valuation.

Chimerix has lower revenue, but higher earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Deciphera Pharmaceuticals and Chimerix, as provided by MarketBeat.com.

Deciphera Pharmaceuticals currently has a consensus target price of $70.30, indicating a potential upside of 54.74%. Chimerix has a consensus target price of $18.00, indicating a potential upside of 123.33%. Given Chimerix's stronger consensus rating and higher possible upside, analysts clearly believe Chimerix is more favorable than Deciphera Pharmaceuticals.

Profitability

This table compares Deciphera Pharmaceuticals and Chimerix's net margins, return on equity and return on assets.

Summary

Chimerix beats Deciphera Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Corcept Therapeutics (NASDAQ:CORT) and Chimerix (NASDAQ:CMRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Corcept Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.

Institutional and Insider Ownership

75.4% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 16.4% of Corcept Therapeutics shares are owned by insiders. Comparatively, 9.0% of Chimerix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Corcept Therapeutics and Chimerix's top-line revenue, earnings per share and valuation.

Corcept Therapeutics has higher revenue and earnings than Chimerix. Chimerix is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Corcept Therapeutics and Chimerix, as provided by MarketBeat.com.

Corcept Therapeutics currently has a consensus target price of $24.00, indicating a potential upside of 4.44%. Chimerix has a consensus target price of $18.00, indicating a potential upside of 123.33%. Given Chimerix's stronger consensus rating and higher possible upside, analysts clearly believe Chimerix is more favorable than Corcept Therapeutics.

Profitability

This table compares Corcept Therapeutics and Chimerix's net margins, return on equity and return on assets.

Summary

Corcept Therapeutics beats Chimerix on 9 of the 14 factors compared between the two stocks.

Organogenesis (NASDAQ:ORGO) and Chimerix (NASDAQ:CMRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Organogenesis has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.

Institutional and Insider Ownership

4.6% of Organogenesis shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 57.2% of Organogenesis shares are owned by insiders. Comparatively, 9.0% of Chimerix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Organogenesis and Chimerix's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Organogenesis and Chimerix, as provided by MarketBeat.com.

Organogenesis currently has a consensus target price of $16.50, indicating a potential downside of 22.21%. Chimerix has a consensus target price of $18.00, indicating a potential upside of 123.33%. Given Chimerix's higher possible upside, analysts clearly believe Chimerix is more favorable than Organogenesis.

Earnings and Valuation

This table compares Organogenesis and Chimerix's top-line revenue, earnings per share and valuation.

Organogenesis has higher revenue and earnings than Chimerix. Organogenesis is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.

Summary

Organogenesis beats Chimerix on 7 of the 12 factors compared between the two stocks.

Chimerix (NASDAQ:CMRX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Insider & Institutional Ownership

45.4% of Chimerix shares are owned by institutional investors. 9.0% of Chimerix shares are owned by company insiders. Comparatively, 41.4% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Chimerix has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Chimerix and Rocket Pharmaceuticals, as reported by MarketBeat.

Chimerix currently has a consensus price target of $18.00, indicating a potential upside of 123.33%. Rocket Pharmaceuticals has a consensus price target of $59.1818, indicating a potential upside of 38.73%. Given Chimerix's stronger consensus rating and higher possible upside, equities analysts plainly believe Chimerix is more favorable than Rocket Pharmaceuticals.

Profitability

This table compares Chimerix and Rocket Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Chimerix and Rocket Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Rocket Pharmaceuticals has lower revenue, but higher earnings than Chimerix. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.

Summary

Rocket Pharmaceuticals beats Chimerix on 7 of the 13 factors compared between the two stocks.

Amicus Therapeutics (NASDAQ:FOLD) and Chimerix (NASDAQ:CMRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.

Volatility & Risk

Amicus Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Amicus Therapeutics and Chimerix, as reported by MarketBeat.

Amicus Therapeutics presently has a consensus price target of $20.0385, suggesting a potential upside of 102.82%. Chimerix has a consensus price target of $18.00, suggesting a potential upside of 123.33%. Given Chimerix's stronger consensus rating and higher probable upside, analysts clearly believe Chimerix is more favorable than Amicus Therapeutics.

Valuation and Earnings

This table compares Amicus Therapeutics and Chimerix's gross revenue, earnings per share and valuation.

Chimerix has lower revenue, but higher earnings than Amicus Therapeutics. Chimerix is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

45.4% of Chimerix shares are held by institutional investors. 2.5% of Amicus Therapeutics shares are held by insiders. Comparatively, 9.0% of Chimerix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Amicus Therapeutics and Chimerix's net margins, return on equity and return on assets.

Summary

Chimerix beats Amicus Therapeutics on 10 of the 14 factors compared between the two stocks.

Chimerix (NASDAQ:CMRX) and Global Blood Therapeutics (NASDAQ:GBT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Chimerix has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Comparatively, Global Blood Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Chimerix and Global Blood Therapeutics, as provided by MarketBeat.

Chimerix currently has a consensus target price of $18.00, suggesting a potential upside of 123.33%. Global Blood Therapeutics has a consensus target price of $90.3158, suggesting a potential upside of 115.45%. Given Chimerix's stronger consensus rating and higher probable upside, analysts clearly believe Chimerix is more favorable than Global Blood Therapeutics.

Valuation and Earnings

This table compares Chimerix and Global Blood Therapeutics' revenue, earnings per share (EPS) and valuation.

Chimerix has higher revenue and earnings than Global Blood Therapeutics. Chimerix is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

45.4% of Chimerix shares are owned by institutional investors. 9.0% of Chimerix shares are owned by company insiders. Comparatively, 4.3% of Global Blood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Chimerix and Global Blood Therapeutics' net margins, return on equity and return on assets.

Summary

Chimerix beats Global Blood Therapeutics on 11 of the 14 factors compared between the two stocks.